



FORESIGHT SEMINARS ON HEALTH & INNOVATION
FORMERLY,
FORESIGHT SEMINARS ON PHARMACEUTICAL RESEARCH AND
DEVELOPMENT
(RENAMED IN 1997)

September 18, 1978 *The Future of Pharmaceuticals: Breakthrough Possibilities, Development Constraints, and Policy Questions*

Jerome E. Schnee, Ph.D., Graduate School of Business
Rutgers University
Frank Standaert, M.D., Department of Pharmacology,
Georgetown University School of Medicine
James Turner, J.D., Swankin & Turner

November 13, 1978 *The Impact of National Health Insurance on Pharmaceutical Research and Development*

Peter Goldschmidt, M.D., M.P.H., M.B.A. of Policy Research, Inc.
Michael Riddiough, Pharm.D., M.P.H. - Senior Analyst, Health Program,
Office of Technology Assessment
John Virts, Ph.D., Corporate Economist, Eli Lilly & Co.

February 13, 1979 *The Rise of Alternatives to Drug Therapies and the Implications for Pharmaceutical R & D*

Sheila Touquan, R.Ph., M.S., J.D., National Drug Program
Coordinator, Blue Cross/Blue Shield Association
Rick J. Carlson, J.D., Senior Associate, Commonwealth Research
Institute and President of Health Resources and
Communications, Inc.
Murray Weiner, M.D., Vice President for Research and Scientific
Affairs, Merrell Research Center

March 19, 1979

The National Center for Clinical Pharmacology: Policy Questions and Long Term Consequences

John Burns, Ph.D., Vice President, Research, Hoffmann-La Roche
Marcia Greenberger, J.D., Director of the Women's Rights Project,
Center for Law and Social Policy
John Oates, M.D., Professor of Medicine and Pharmacology and
Director of Clinical Pharmacology, Vanderbilt University
School of Medicine

May 15, 1979

The Impact of Regulation and Incentives for Pharmaceutical Research and Development

William S. Comanor, Ph.D., Director, Bureau of Economics, Federal
Trade Commission
Leon I. Goldberg, Ph.D., M.D., Professor of Pharmacology and
Medicine and Director of Clinical Pharmacology,
University of Chicago
Hubert C. Peltier, M.D., Senior Vice President of Research, Merck,
Sharp, and Dohme Research Laboratories

June 11, 1979

Recombinant DNA and New Drugs: Science, Policy, and Ethics

LeRoy Walters, Ph.D., Director, Georgetown University Center
for Bioethics of the Kennedy Institutes of Health
Burke Zimmerman, Ph.D., Director, Division of Legislative
Analysis, National Institutes of Health
Herbert Weissback, Ph.D., Associate Director, Roche Institute of
Molecular Biology

November 6, 1979

Decision-Making Factors in Drug Regulation: Reevaluation of Drug Safety and Efficacy

Joseph T. Curti, M.C., Vice President and Medical Director, Pfizer
Pharmaceuticals
James Turner, J.D., Swankin & Turner
William M. Wardell, M.D., Ph. D., Associate Professor of Pharmacology,
Toxicology, and of Medicine and Director of the Center for the
Study of Drug Development, University of Rochester School of
Medicine and Dentistry

January 29, 1980 ***Unmet Needs for Pharmaceutical Research and Development:
Orphan Drugs***

Seymour Cohen, Ph.D., Distinguished Professor, Department of
Pharmacological Sciences, State University of New York
Clifford Joseph, M.D., Associate Medical Director, Hoffmann-La Roche
Barrett Scoville, M.D., Epilepsy Branch, Neurological Disorders Program
of the National Institute of Neurological and Communicative
Disorders and Strokes, National Institute of Health

February 26, 1980 ***The Environments for Optimal Research***

J. Richard Crout, M.D., M.S., Director, Bureau of Drugs, U.S. Food and
Drug Administration
Richard Faust, Ph.D., M.B.A., Director of Research Planning, Hoffmann-
La Roche, Inc.
Henry Grabowski, Ph. D., Economist, Division of Economic Analysis,
Health Care Financing Administration, Department of Health,
Education and Welfare

March 18, 1980 ***Health Outcome Measures: Implications for Drug R & D***

Peter G. Goldschmidt, M.D., M.P.H., Vice President of Policy Research
C. Norman Shealy, M.D., Ph.D., Director, Pain and Rehabilitation
Center and President of the American Holistic Medical

Association

Leonard Shifrin, Ph.D., Professor of Economics, College of William and
Mary

April 21, 1980 ***Nutrition Research and New Therapies***

Myron Brin, Ph.D., Director, Department of Clinical Nutrition,
Hoffmann-La Roche Inc.
Michael Lerner, Ph.D., President and Executive Director of Commonweal,
a California health and educational resource center
Myron Winick, M.D., Director, Institute of Human Nutrition, Columbia
University's College of Physicians and Surgeons

May 20, 1980 ***Recombinant DNA, New Drugs, and Societal Choice***

L. Patrick Gage, Ph.D., Director, Laboratory for Recombinant DNA
Research, Hoffmann-La Roche, Inc.
Gretchen Kolsrud, Ph.D., Program Manager, Population and Genetics,
Office of Technology Assessment
John Platt, Ph.D., Lecturer, Boston University School of Medicine

November 12, 1980 ***Drug Patents: The Impact of Restoring Patent Life Lost***

Henry Grabowski, Ph.D., Professor of Economics, Duke University
Alan Louri, Ph.D., J.D., Vice President for Corporate Patents and
Assistant General Counsel, SmithKline Corporation

December 2, 1980 ***Orphan Drugs: Adjustments in the Approval Process?***

Thomas Althuis, Ph.D., Senior Associate, Public Affairs Division, Pfizer
Irving Ladimer, J.D., S.J.D., Director, Health Services and Medical
Malpractice Programs, Research Institute, American Arbitration
Association
Barrett Scoville, M.D., Special Expert, Drug Development, Epilepsy
Branch, Neurological Disorders Program, National Institute of
Neurological and Communicative Disorders and Stroke

February 10, 1981 ***Pharmaceutical R&D and Regulation: Background Overview
for the 97th Congress***

Peter Hutt, Partner, Covington and Burling
James Turner, Partner, Swankin and Turner

March 3, 1981

***Can Infectious Diseases Be Controlled: What Have We
Learned from Antibiotics?***

Harold Neu, M.D., Professor of Medicine and Pharmacology, Columbia University College of Physicians and Surgeons and Chief of the Division of Infectious Diseases, Columbia Presbyterian Medical Center

Claude Nash, Ph.D., Associate Director of Microbiology, Smith, Kline & French Laboratories

Richard Novick, M.D., Chariman, Department of Plasmid Biology, and Director of the Public Health Research Institute of the City of New York

July 21, 1981

***The Drug Regulatory Process: The Impact of Changing
Procedures Before and After Market Approval***

Marcia Greenberger, Managing Attorney, National Women's Law Center
Ronald W. Hansen, Associate Director, Center for Research in Government Policy and Business, Graduate School of Management, University of Rochester

William W. Vodra, Associate, Arnold and Porter

September 22, 1981

Achieving Nutrient Adequacy: Health and Policy Issues

Myron Brin, Ph.D., Director, Clinical Nutrition, Hoffmann-La Roche Inc.

Katherine L. Clancy, Ph.D., President, Society for Nutrition Education

Eleanor M. Pao, Ph.D., Nutritionist, Consumer Nutrition Center, U.S.D.A.

February 8, 1982

Frontiers of Drug Discovery

Katherine L. Bick, Ph.D., Acting Deputy Director of the National Institute of Neurological and Communicative Disorders and Stroke

Craig D. Burrell, M.D., Vice-President and Director of External Affairs, Sandoz, Inc.

Karen Gale, Ph.D., Pharmacology Department, Georgetown University Schools of Medicine and Dentistry

Foresight Seminar Topics List

March 3-4, 1982

Conference: Pharmaceuticals in the Year 2000
Held at Project Hope's Health Study Center

Welcome

Howard L. Binkley
Institute for Health Policy
Project HOPE

Policy Directions in the
Current Health Care Context

William Walsh, M.D., President
Project HOPE

The Task of the
Conference

Clement Bezold, Ph.D., Director
Institute for Alternative Futures

Images of the Year 2000

Harry Schwartz, Ph.D., Writer in
Residence, College of Physicians
and Surgeons, Columbia University

Health Conditions in the
Year 2000

Peter G. Goldschmidt, M.D., Dr.P.H.
Director, Health Services Research
and Development Service, Veterans
Administration

Research Breakthroughs
by the Year 2000

Jane J. Stein, Contributing Editor,
National Journal, author of *Making
Medical Choices*

Government Policies and
the Development of New
Drugs

Edward Burger, M.D., Sc.D., Director,
Institute for Health Policy Analysis,
Georgetown University

The Pharmaceutical
Industry in the Year 2000

Herbert J. Conrad, Vice President,
Pharmaceuticals, Hoffmann-La Roche
Inc.

Communications,
Consumers &
Pharmaceuticals

James S. Turner, J.D., Partner,
Swankin & Turner

Panel Discussion

J. Richard Crout, M.D., Director
Bureau of Drugs, Food and Drug
Administration

March 3-4, 1982 *Conference: Pharmaceuticals in the Year 2000 (cont.)*

Jonah Shacknei, Counsel to the
Chairman House Science and
Technology Subcommittee on
Natural Resources

Ronald F. Docksai, Ph.D.
Majority Health Director
Senate Labor and Human
Resources Committee

Henry Grabowski, Ph.D.
Professor of Economics
Duke University

March 23, 1982 *The Recommendations of the Commission on the Federal Drug
Approval Process*

Barry M. Bloom, Ph.D., President, Pfizer Central Research
Louis Lasagna, M.D., Professor of Pharmacology and Toxicology and
Professor of Medicine, University of Rochester School of
Medicine
William W. Vodra, J.D. Of Counsel, Arnold and Porter

May 24, 1982 *Issues on Drug Testing*

Norman Lavy, M.D., Vice President, Drug Regulatory Affairs, E.R.
Squibb & Sons Inc.
Lawrence Miike, M.D., J.D., Senior Analyst Division of Health and Life
Sciences, Congressional Office of Technology Assessment
Robert Temple, M.D., Acting Associate Director for New Drug
Evaluation, Food and Drug Administration

July 13, 1982 *The Future of Research Productivity*

Joseph Perpich, M.D., J.D., Vice President for Corporate Planning and
Administration
Denis Prager, Ph.D., Assistant Director for Life Sciences and Institutional
Relations, Office of Science and Technology Policy, Executive
Office of the President
Jacob C. Stucki, Ph.D., Vice President for Pharmaceutical Research, The
Upjohn Company

September 26, 1982 *The Future of Coronary Heart Disease: Prevention, Treatment and Cure*

Peter L. Frommer, M.D., Deputy Director, National Heart, Lung, and Blood Institute

Russell Jaffe, M.D., Ph.D., Consulting physician in health promotion

Robert B. Wallace, M.D., Professor and Chairman of the Department of Surgery, Georgetown University Medical Center

November 16, 1982 *Animal Testing and New Drugs*

A. M. Guarino, Ph.D., Review Scientist, New Drug Evaluation, National Center for Drugs and Biologics, FDA

Franklin M. Loew, D.V.M., Ph.D., Dean, Tufts University School of Veterinary Medicine

David Phelen, D.V.M., Director of Laboratory Animal Science, SmithKline and French Laboratories

Andrew N. Rowan, D.Phil., Associate Director, The Institute for the Study of Animal Problems of the Humane Society of America

December 15, 1982 *The Future of Biotechnology*

Eric Drexler, S.M., Research Affiliate, MIT Space Systems Laboratory

Gretchen Kolsrud, Ph.D., Program Manager, Population and Genetics, Office of Technology Assessment

Kevin Ulmer, Ph.D., Director, Exploratory Research, Genex Corporation

February 9, 1983 *Pharmaceutical Research and Development Issues in the 98th Congress*

Michael J. Hurley, J.D., Senior Associate, Booz-Allen & Hamilton Inc.

Stuart J. Land, J.D., Senior Partner, Arnold & Porter

Joseph Levitt, J. D., Associate Chief Counsel, Food and Drug Division, Office of the General Counsel for the Department of Health and Human Services

March 15, 1983 ***Brain Research and National Research Policy***

Mental Lee Goldman, Chief of Planning and Analysis, National Institute of
Neurological & Communicative Disorders & Stroke (NIN/CDS)
Frederick Goodwin, M.D., Scientific Director, National Institute of
Health (NIMH)
Donald F. Klein, M.D., Director of Psychiatric Research at the New York
State Psychiatric Institute

April 11, 1983 ***Research and Development in the Global Pharmaceutical
Economy***

Tamara J. Erickson, M.B.A., Manager of the Pharmaceutical Unit,
Arthur D. Little, Inc.
Robert E. Stein, LL.B., Attorney at Law, President of Environmental
Mediation International
William M. Wardell, M.D., Ph.D., Director of the Center for the Study of
Drug Development, University of Rochester School of Medicine
and Dentistry

June 13, 1983 ***National Research Policy and Research into the Conditions
of Aging***

James F. Fries, M.D., Associate Professor of Medicine, Stanford
University
Edward L. Schneider, M.D., Associate Director for Biomedical Research
and Clinical Medicine, National Institute on Aging
R. Knight Steel, M.D., Director of the Gerontology Center, Boston
University School of Medicine

November 10, 1983 ***Cost Containment and Biomedical Research***

Paul Ginsburg, Ph.D., Deputy Assistant Director for Income Security and
Health, Congressional Budget Office
Helen L. Smits, M.D., Associate Professor of Medicine and Public Health,
Yale School of Medicine
Burton A. Weisbrod, Ph.D., Professor of Economics, University of
Wisconsin

February 2, 1984 *The Future of Cancer: Prevention, Treatment and Cure*

Loretta M. Itri, M.D., Director of Clinical Oncology, Hoffman-La Roche
Michael Lerner, Ph.D., President, Commonweal
Edward Sondik, Ph.D., Chief of Operations, Research Branch, Division of
Cancer Prevention and Control, National Cancer Institute

June 5, 1984 *The Future of Organ Transplantation*

Gary E. Friedlaender, M.D., Yale University Orthopedic Surgeon and
President of the American Council on Transplantation
Kenneth W. Sell, M.D., Ph.D., Scientific Director, National Institute of
Allergy and Infectious Diseases
Samuel Gorovitz, Ph.D., University of Maryland

July 30, 1984 *The Information Revolution in Health Care*

James F. Fries, M.D., Associate Professor of Medicine, Stanford
University
Robert L. Kane, M.D., Senior Researcher, Rand Corporation and
Professor, U.C.L.A., School of Medicine
Marilyn Bergner, Ph.D., Professor of Health Services, University of
Washington, Seattle

October 16, 1984 *The Future of Drugs and the Elderly*

William B. Abrams, M.D., F.A.C.P., Executive Director for Scientific
Development, Merck Sharp & Dohme Research Laboratories
Robert Temple, M.D., Director, Office of Drug Research and Review,
Food and Drug Administration's National Center for Drugs and
Biologics
Julian Fisher, M.D., Executive Vice President, Computers in Medicine,
Faculty, Harvard Medical School

November 13, 1984 *The Future of Diagnostic Testing*

S. Raymond Gambino, M.D., Executive Vice President and Chief Medical
Officer, MetPath, Inc. and Adjunct Professor of Pathology at
Columbia University
Judith Wagner, Ph.D., Senior Analyst, U.S. Congress Office of
Technology Assessment Health Program
Magdalena Usategui, Ph.D., Director, Roche Diagnostic Systems

March 4, 1985 *The Prospects for Home Health Care*

Joshua Wiener, Ph.D., Senior Fellow, Brookings Institution
Frederick R. Curtiss, Ph.D., R.Ph., Vice President of Reimbursement
Services, HPI Health Care Services, Inc., and Adjunct Assistant
Professor, School of Pharmacy, University of Southern California
Robert Harootyan, Project Director and Senior Analyst, Office of
Technology Assessment

September 3, 1985 *Nuclear Medicine and Low-Level Radioactive Waste*

David M. Berick, Director, Nuclear Waste and Safety Project,
Environment Policy Institute
Richard Guimond, Director, Criteria and Standards Division, Office of
Radiation Programs of the Environmental Protection Agency
Henry N. Wagner, Jr., M.D., Professor of Medicine and Radiology, John
Hopkins University School of Medicine and Professor of
Environmental Health Sciences, John Hopkins School of Hygiene
and Public Health

November 7, 1985 *The Future of the FDA*

Mark Novitch, M.D., Corporate Vice President, The Upjohn Company
and former Deputy Commissioner of the FDA
William W. Vodra, Associate, Arnold and Porter (in place of Eugene M.
Pfeifer)
Peter H. Rheinstein, M.D., J.D., M.S., Director, Office of Drug Standards,
Center for Drugs and Biologics, FDA

February 17, 1987 *International Trade, Competition, and the U.S. Pharmaceutical
Industry*

Tamara J. Erickson, Corporate Vice President and Manager of the Health
Industries Management Section of Arthur D. Little, Inc.
Jay J. Kingham, Senior Vice President for International Affairs of the
Pharmaceutical Manufacturers Association
Harvey E. Bayle, Jr., Assistant U.S. Trade Representative for Trade Policy
and Analysis

March 18, 1987 ***Biotechnology and the Regulation of Pharmaceuticals***

Samuel Ackerman, M.D., Vice President for Medical and Regulatory
Affairs with the Xoma Corp.
Ralph Christoffersen, Vice President for Biotechnology and Basic
Research Support for the Upjohn Company
SmithKline George Poste, M.D., Vice President and Director of R&D with
and French Laboratories Corporation

April 16, 1987 ***Access to Pharmaceuticals in a Changing Health Care System***

Willis B. Goldbeck, President of the Washington Business Group on
Health and Founder and Consulting Editor of *Business and Health*
Vincent R. Gardner, President of Vince Gardner Associates and Associate
Professor of Pharmacy Administration at the University of Texas
at Austin
Michael A. Riddiough, President of the consulting firm Riddiough and
Associates, pharmacist and public health expert

September 15, 1987 ***Pharmaceutical R&D and The Future of Geriatric Medicine***

Darrell R. Abernethy, M.D., Ph.D., Director, Division of Clinical
Pharmacology and Associate Professor of Medicine, Brown
University
William B. Abrams, M.D., F.A.C.P., Executive Director for Scientific
Development, Merck Sharp & Dohme Research Laboratories and
Adjunct Professor of Medicine at Jefferson Medical College
Ronald W. Hart, Ph.D., Director, National Center for Toxicological
Research of the Food and Drug Administration

October 14, 1987 ***AIDS Research: Vaccines and Treatment***

David W. Barry, M.D., Vice President of Research and Head of the
Department of Virology at the Burroughs Wellcome Co.
Anthony S. Fauci, M.D., Director of the National Institute of Allergy and
Infectious Diseases (NIAID) of the National Institutes of Health
Michael E. Samuels, Dr. P.H., Assistant to the Surgeon General, U.S.
Public Health Service

December 16, 1987 ***Product Liability and Pharmaceutical R&D***

Zolla P. Horovitz, Ph.D., Vice President, Research Administration,
Planning & Scientific Liaison at the Squibb Institute for Medical
Research

Geoffrey R.W. Smith, J.D., Counsel, McCutchen, Doyle, Brown &
Enersen and former Associate General Counsel, Pharmaceutical
Manufacturers Association

Marianna S. Smith, J.D., Executive Director, Mannville Personal Injury
Settlement Trust

March 15, 1988 ***Generic Drugs and Bioequivalence***

William Barr, Pharm. D., Ph.D., Professor and Chairman, Department of
Pharmacy and Pharmaceutics, Virginia Commonwealth
University's Medical College

Anthony R. DiSanto, Ph.D., Vice President, Drug Delivery Research and
Development, The Upjohn Company

Dee Fernsterer, President, Generic Pharmaceutical Industry Association

March 31, 1988 ***Alzheimer's Disease and Pharmaceutical Development***

John P. Blass, M.D., Ph.D., Professor, Department of Neurology and
Medicine, Chief, Division of chronic and Degenerative Diseases,
Cornell University's Medical College, Staff Physician and
Director, Dementia Research Service, Burke Rehabilitation Center,
New York

Office of Zaven S. Khachaturian, Ph.D., Associate Director, Office of Neuroscience
and Neurobiology of Aging Program, NIA and Director,
Alzheimer's Disease Research at NIH

Richard J. Wurtman, M.D., scientist, Harvard Medical School and
Director, Clinical Research Center at Massachusetts Institute of
Technology (MIT)

May 11, 1988 ***Animal Testing and New Model Systems***

Alan M. Goldberg, Ph.D., Director, Center for Alternatives to Animal
Testing (CAAT), Johns Hopkins University

Emil Alvin Pfitzer, M.Sc., Sc.D., Assistant Vice President, Group
Director, Department of Toxicology and Pathology, Hoffmann-La
Roche Inc.

Henry Spira, Coordinator of animal rights coalitions has led efforts to
abolish the LD-50 test and the Draize Rabbit Blinding Test.

June 21, 1988

Ethical Issues in Genetic Testing

Walter Truett Anderson, Ph.D., author and political scientist who has studied the politics of biotechnology and genetic resources
Neil Anton Holtzman, M.D., M.P.H., Professor of Pediatrics, Johns Hopkins University School of Medicine and Professor of Epidemiology in the School of Hygiene and Public Health
Philip R. Reilly, J.D., M.D., Director, Eunice Kennedy Shriver Center University Affiliated Program

September 14, 1988

Economics of Genetic Testing, Disease Prevention and Treatment

Robert M. Greenstein, M.D., Professor of Pediatrics, University of Connecticut Health Center and Director, Division of Child and Family Studies
Lester Lave, Ph.D., James H. Higgins, Professor of Economics, Carnegie-Mellon University and author
J. Howard Beales, III, Ph.D., Assistant Professor of Business Administration, George Washington University and former Chief, Human Resources and Housing Branch, Office of Information and Regulatory Affairs, Office of Management and Budget

October 17, 1988

The Future of the FDA Drug Approval Process

Gerald J. Mossinghoff, President, Pharmaceutical Manufacturers Association
Gary L. Neil, Ph.D., Divisional Vice President for Biotechnology and Basic Research Support for The Upjohn Company
William B. Shultz, J.D., Attorney for Public Citizens Litigation Group
Robert Temple, M.D., Director, Office of Drug Evaluation I, Center for Drug Evaluation and Research of the Food and Drug Administration

March 22, 1989

Clinical Trials in the 1990s: New Methodologies for Drug Review

Larry Bruni, M.D., President, National Community Research Initiatives and physician who works with HIV positive patients

Judith K. Jones, M.D., Ph.D., President, The Degge Group, former Director of the FDA Division of Drug Experience and faculty member of the Georgetown University School of Medicine

Steven Kahane, M.D., M.S., Senior Vice President, Clinical Information Advantages, Inc. and former Director, Systems Development and Information Systems at Johns Hopkins University

Louis Lasagna, M.D., Chairman, President's National Committee to Review Current Procedures for Approval of New Drugs for Cancer and AIDS and Director, Center for the Study of Drug Development at Tufts University

Robert Temple, M.D., Director, Office of Drug Evaluation I, Center for Drug Evaluation and Research of the Food and Drug Administration

April 14, 1989

Controlling Health Care Costs While Ensuring Quality

Philip Caper, M.D., President, Codman Research Group, Inc.; Professor of Public Policy, Dartmouth Medical School; lecturer in Social Medicine and Health Policy at Harvard university's School of Medicine; and former professional staff member of the Senate Labor and Human Resources Subcommittee on Health

Kathleen Lohr, Ph.D., Senior Professional Associate and Study Director, Institute of Medicine/National Academy of Sciences' Division of Health Care Services and Council on Health Care Technology, and former health Policy analyst for The Rand Corporation

Maria Michnich, Dr.P.D., Associate Executive Vice President for Health Policy, American College of Cardiology; and former health staff member for Senator Robert Dole

June 26, 1989

The Politics of Health Care in the 1990s

Glenna Crooks, Ph.D., Senior Director of Public Policy, Merck & Co., former Deputy Assistant Secretary for Health, Department of Health and Human Services

Robert Helms, Ph.D., Executive Director, American Pharmaceutical Institute, former Assistant Secretary for Planning and Evaluation and Deputy Assistant Secretary for Health Policy, Department of Health and Human Services

John Iglehart, editor and creator of the journal *Health Affairs* and national correspondent for *The New England Journal of Medicine*

Stephan Lawton, partner, Reed, Smith, Shaw & McClay and former Chief Counsel for the Subcommittee on Health and the Environment, Committee on Interstate and Foreign Commerce

John Middleton, President, Diversified Pharmaceutical Services, Inc. and former Vice President of Pharmacy Programs, United HealthCare Corporation

September 22, 1989

Consumer Activism and the Drug Approval Process

Abbey Meyers, Founder and Executive Director, National Organization for Rare Disorders (NORD), member of the Board of Directors, National Health Council

Lloyd Ney, Founder, Patient Advocates for Advanced Cancer Treatments (PAACT), editor of *Golden Years* newsletter for senior citizens and *Cancer Communication* which informs readers of cancer research, legislation and therapies

Rebecca Smith, Study Coordinator, Community Research Initiative; board member, AIDS Treatment Registry; member of the Treatment and Data Committee for the organization AIDS Coalition to Unleash Power (ACT UP)

November 15, 1989

The Future of Marketing Medicines

David Lefkowitz, M.D., President, Physicians Pharmaceutical Network, and a practicing physician

Donald Rucker, Ph.D., Commissioner, Prescription Drug Payment Review Commission for the Office of Technology Assessment, economist, professor and Head, Department of Pharmacy Administration, University of Illinois at Chicago

Peter Seaver, Corporate Officer and Vice President, Worldwide Pharmaceutical Marketing at The Upjohn Company

December 11, 1989 *The Cost of Developing Medicines*

Judy C. Lewent, Vice President and Treasurer, Merck & Co., Inc.
Hollings C. Renton, Executive Vice President and Chief Operating
Officer, Cetus Corporation
W. Leigh Thompson, Jr., M.D., Ph.D., Group Vice President, Lilly
Research Laboratories, Eli Lilly and Company; and Professor of
Medicine, Indiana University School of Medicine

March 14, 1990 *The Affordability of Medicines*

Robert Hills, Executive Director, National Customers and Policy, Merck
Sharp & Dohme Division of Merck & Co., Inc.
Sanford Luger, R.P., Chief Pharmacy Consultant, New Jersey Medicaid
Program
Stephen Schondelmeyer, Ph.D., Professor, Purdue University
Pharmaceutical Economics Research Center

April 17, 1990 *Formularies: Impacts on Health Care Costs and
Pharmaceutical Innovation*

Robert J. Newman, Ph.D., Professor and Partnership for Research
Excellence Fellow, Department of Economics, Louisiana State
University
Aaron Johnson, Commissioner, Georgia Department of Medical
Assistance
Peter Singleton, M.D., Professor of Medicine, Meharry Medical College
Norrie Wilkins, M.D., Vice President, Pharmaceutical Management,
Partners National Health Plans

May 21, 1990 *Rationing Health Care*

Dave Kears, Director, Alameda County Health Care Services
The Honorable Rick Kotulski, Representative, Oregon State Legislature
Linda Schofield, Director, Connecticut Medical Care Administration

June 28, 1990 *National Health Funding: Effects on Innovation, Access and Quality*

Jacques Krasny, Director and Managing Principal, Bogart Delafield Ferrier Inc.
Robert Neimeth, Vice President of Pfizer, Inc. and Executive Vice President of Pfizer International Inc.
Albert Wertheimer, Ph.D., Dean, Philadelphia College of Pharmacy and President, Academic Section of FIP (International Pharmaceutical Federation)

September 10, 1990 *Long-Term Care: Problems and Opportunities*

Peter P. Lamy, Ph.D., Sc.D., Professor, Geriatrics, Family Medicine, Epidemiology and Preventive Medicine, Assistant Dean of Geriatrics, and Director, Center for the Study of Pharmacy and Therapeutics for the Elderly, University of Maryland School of Medicine
Glenda J. Motta, R.N., President of GM Associates and past president of the International Association for Enterostomal Therapy
R. Tim Webster, Executive Director, American Society of Consultant Pharmacists
Michael D. Young, M.D., Ph.D., Corporate Director Worldwide Regulatory Affairs, R&D, The Procter & Gamble Company

October 29, 1990 *The Role of the FDA in the 1990s*

Arthur Hull Hayes, Jr., M.D., President and CEO, EM Pharmaceuticals Inc., former Assistant Surgeon General and former Commissioner of the U.S. Food and Drug Administration
Peter Barton Hutt, Esq., Partner, Covington & Burling, and former Chief Counsel for the U.S. Food and Drug Administration
Alexander MacKay Schmidt, M.D., Vice President and Director, Technology Advancement Center, University Hospital Consortium, Inc., and former Commissioner of the U.S. Food and Drug Administration

March 27, 1991 ***Cost Containment and Pharmaceutical Prices: Policy Goals and Consequences***

Susan D. Horn, Ph.D., Professor, Department of Health Policy and Management, Johns Hopkins School of Hygiene and Public Health; and Director, Robert Wood Johnson Foundation Program for Faculty Fellowships in Health Care Finance

Andy Stergachis, Ph.D., Associate Professor of Pharmacy and Epidemiology; and Director of the Program in Pharmacoepidemiology and Drug Policy, University of Washington School of Pharmacy

Darwin E. Zaske, Pharm. D., Professor, University of Minnesota College of Pharmacy; and Director of Pharmaceutical Services, St. Paul-Ramsey Medical Center

April 22, 1991 ***Treatment Protocols and Outcome Measures: Future Directions***

David M. Angaran, M.S., Professor and Department Chairman, and Associate Director of Pharmacy at Shands University of Florida College of Pharmacy

William T. McGivney, Ph.D., Director, Division of Health Care Technology, American Medical Association

Stephen C. Schoenbaum, M.D., M.P.H., Deputy Medical Director, Harvard Community Health Plan; and Associate Professor of Medicine, Harvard Medical School

May 10, 1991 ***Negotiated Drug Prices: Impact on the Private Sector***

Roger Green, Principal, Roger Green & Associates; consultant for pharmaceutical clients; author of recent article forecasting how manufacturers will respond to new incentives coming from negotiated drug prices in Medicaid program

Daniel R. Hawkins, Jr., Director of Policy Analysis, National Association of Community Health Centers

James C. McAllister, M.S., Director of Pharmacy Services, Duke University Medical Center; and President, American Society of Hospital Pharmacists

September 10, 1991 ***Evaluating Cost Effectiveness: Future Requirements for Drug Approval and Reimbursement***

- David B. Evans, Ph.D., Health Economist, World Health Organization; former consultant to Australia's Pharmaceutical Benefits Advisory Scheme on guidelines for cost effectiveness studies
- Alan L. Hillman, M.D., M.B.A., Assistant Professor, University of Pennsylvania's School of Medicine and the Wharton School; and Director, Center for Health Policy at the Leonard Davis Institute of Health Economics; lead author of recent article in *The New England Journal of Medicine* calling for ethical guidelines in the conduct of cost effectiveness studies
- Louis A. Morris, Ph.D., Chief, Food and Drug Administration (FDA) Marketing Practices and Communications Branch; and Scholar-in-Residence, Center for Marketing and Public Policy Research, American University; currently serves part time as marketing and consumer research consultant at the Federal Trade Commission

October 7, 1991 ***Drug Approvals in the U.S. and Abroad***

- D. Bruce Burlington, M.D., Deputy Director, Scientific and Medical Affairs, and Deputy Director of the Office of Drug Evaluation II at the FDA
- Brenton E. James, Senior Regulatory Affairs Advisor for Glaxo Group Research Ltd. in the U.K.
- Kenneth P. Wolski, M.D., Vice President, Strategy and Policy, Merck, Sharp & Dohme Research Laboratories

November 19, 1991 ***Prescribing Pharmaceuticals for Uses not Approved by the FDA***

- Joseph S. Bailes, M.D., Chairman, Clinical Practice Committee, American Society of Clinical Oncology and board-certified oncologist; and Clinical Assistant Professor, University of Texas Health Science Center at San Antonio
- Kenneth W. Johnson, Director, Drug Information Division, United States Pharmacopeial Convention, Inc.
- Joel E. Miller, Director, Professional Services for the Health Association of America

July 6, 1992 ***Drug Utilization Review: Beyond the Next Phase***

Bill Abrams, M.D. Merck Research Labs	Gary Erwin, Pharm.D. Philadelphia College of Pharmacy	Steve Mullenix, R. Ph. Q A, Inc.
Jan Brandenburg First Virginia Health Services	Tom Fulda Health Care Financing Adm.	Jeff Sanders Health Care Financing
Jerry Brager American Medical Assoc.	Edward Lennard, Pharm.D. Health Information Designs	Jerome Seidenfield, Ph.D. American Medical Assoc.
Tricia Byrns, M.D. University of Colorado	Aida LeRoy, Pharm.D. PharMark, Corp.	James Smith Ameritech
Ted Collins Ctr. for Health Systems Research and Analysis	M. Lee Morse PharMark Corp.	Tom Snedden PACE

August 20, 1992 ***Managed Care and the Pharmaceutical Industry***

Janet Corrigan, National Committee for Quality Assurance
Dennis Longstreet, Ortho Biotech Inc.
David McLean, Clinical Pharmacy Advantage
David Miller, Maryland Pharmacist Association
Ed Moy, Health Care Finance Administration
Jeff Sanders, Health Care Finance Administration
Eleanor Socholitzky, Blue Cross & Blue Shield Massachusetts
William Tindall, Academy of Managed Care Pharmacy

September 21, 1992 ***The Future of Pharmaceutical Pricing***

Mick Kolassa, Research Associate, University of Mississippi Research
Institute of Pharmaceutical Sciences Health Services Research
Division
Steven W. Schondelmeyer, Ph.D., Professor, College of Pharmacy,
University of Minnesota College of Pharmacy; holds the nation's
first Endowed Chair in Pharmaceutical Management and
Economics

November 9, 1992 ***International Markets and Pharmaceutical Prices***

Fredrik Andersson, Ph.D., Research Scientist, Battelle's Medical Technology and Policy Center in London; authored numerous reports on international comparisons of health care expenditures
Jonathan Ratner, Ph.D., Assistant Director for Medicare and Medicaid issues at U.S. General Accounting Office; taught economics at Wellesley College and at SUNY-Albany

December 14, 1992 ***Pharmaceutical Research and Special Populations***

Lionel Edwards, M.D., Assistant Vice President and Senior Director, International Clinical Research, Hoffmann- La Roche
Barry Gurland, M.D., Director, Columbia University Center for Geriatrics and John E. Borne Professor of Clinical Psychiatry
Marianne J. Legatto, M.D., Associate Professor of Clinical Medicine, Columbia University of Physicians and Surgeons; and director of Post Graduate Medical Education, St. Luke's-Roosevelt Institute for Health Sciences
Theresa Radebaugh, S.c.D., Chief, Dementias of Aging Branch, Neuroscience and neuropsychology of Aging Program, National Institute on Aging
Stephen Spielberg, M.D., Ph.D., Executive Director, Exploratory Biochemical Toxicology, Merck, Sharpe & Dohme

December 21, 1992 ***Health Care Reform and Access to Pharmaceuticals***

Clement Bezold, Ph.D., Executive Director, Institute for Alternative Futures
Dan Durham, Legislative Representative, American Association of Retired Persons
Lynn Etheredge, Health Care Consultant
Donald Lee, Vice President, Professional Affairs, Procter & Gamble
Lawrence Lewin, Chairman, Lewin ICF Health and Income Group
Barbara Redman, Executive Director, American Nursing Association

June 11, 1993 ***Future Medicines and National Health Reform***

Gene Cohen, National Institute on Aging
Joe Jacobs, NIH, Office of Alternative Medicine
Jack Killen , NIAID
John Weeks, American Association of Naturopathic Physicians
Mark Zukowski, Amgen

July 23, 1993 *The Price of Future Medicines*

Susan Blumenthal, M.D., M.P.A., Chief, Behavioral Medicine, National
Institute of Mental Health
Rick Carlson, J.D., Author and Consultant
James Gordon, M.D., Director, The Center for Mind-Body Studies
Thomas Pyle, Senior Advisor, The Boston Consulting Group
Richard Studer, President, Consumer Perception Strategies, Inc.

September 24, 1993 *Pharmaceutical Marketing During the Information
Revolution*

Clement Bezold, Ph.D., Institute for Alternative Futures
Kenneth Cohen, National Pharmaceutical Council
William Tierney, Regenstrief Institute for Health Care, Indiana University
School of Medicine

November 1, 1993 *A Universal Drug Benefit*

Jerry Avorn - Harvard Medical School
Howard Cohen - House Energy & Commerce Committee
John Coster - Senate Special Committee on Aging
Scott Harrison - Congressional Budget Office
Roy Ramthun - Senate Finance Committee
Louise Rodrigues - Department of Veterans Affairs
David Schulke - Representative Wyden
Bill Schultz - House Energy & Commerce Committee

December 3, 1993 *Incentives for Prevention in Health Care Reform*

Halley Faust, M.D., MPH - Medmax Services, Inc.
William Harlan, M.D. - Office of Disease Prevention, NIH
John Siegfried, M.D. - Pharmaceutical Manufacturers Association

December 10, 1993 *Technology Assessment for Pharmaceuticals in Health
Care Reform*

Harold J. DeMonaco - Massachusetts General Hospital
Wayne A. Ray - Vanderbilt University
Thomas V. Holohan - Agency for Health Care Policy Research (AHCPR)

February 16, 1994 *Safety, Efficacy and Cost Effectiveness: Policies for the 21st Century*

Louis Lasagna, M.D. - Center for the Study of Drug Development
Bryan Luce, Ph.D., M.B.A. - Battelle Medical Technology and Policy
Research Center
Robert Temple, M.D. - Food and Drug Administration
Ann Witt - Food and Drug Administration

June 9, 1994 *Health Reform and the Future of Innovation*

Rebecca Henderson - MIT Sloan School
Steven Wheelwright - Harvard University

October 7, 1994 *Innovation in Care Delivery: Disease Management Systems*

Sandra Kretz - Quantum Health Resources, Inc.
Douglas Stickney - Quantum Health Resources, Inc.
Roman Yanda - USC School of Medicine

November 10, 1994 *Innovation and Regulation: Models for Reengineering*

Peter Bewley - NovaCare, Inc.
Douglas Michael - University of Kentucky School of Law

December 2, 1994 *Human Genome Project: Implications for the Future of Biotechnology*

Dr. Marty Rosenberg - SmithKline Beecham Pharmaceuticals
Dr. Paula Gregory - National Center for Human Genome Research, NIH

April 28, 1995

Pharmaceutical Policy for the Future

Kenneth Kaitin, Ph.D., Associate Director, Tufts Center for the Study of Drug Development
Catherine Lorraine, Director, Policy Development and Coordination Staff, FDA
Gerald Meyer, Health Sector Vice President for Regulatory Affairs, BBN Software Product Co. & former Acting Director, Center for Drug Evaluation and Research, FDA
Carl Peck, M.D., Director, Center for Drug Development Science, Georgetown University Medical Center

August 21, 1995

Vision and FDA Reform

An invitational workshop

September 28, 1995

The Pharmaceutical Marketplace

Leslie G. Epstein, P.D., Vice President of Managed Care Relations for Advance Paradigm, Inc.
John A. Gans, Pharm.D., Executive Vice President and CEO of the American Pharmaceutical Association (APhA)
Robert N. Merold, Vice President of Marketing and Business Development for IMS America, a Dun & Bradstreet Company
Ronald J. Streck, President and CEO of the National Wholesale Druggists' Association (NWDA)

November 17, 1995

The Third-Wave Marketplace and the Future of Medicaid and Medicare

Mary Kennesson, Senior Associate with Pacific Health Policy Group
Paul Rothman, Executive Director of Frontier Health Services of Miami, Florida
Leonard Kirschner, Vice President for Health Care Initiatives for EDS

December 1, 1995 ***Frontiers in Pharmaceutical Innovation***

Dr. Lloyd M. Smith, Professor of Chemistry at the University of Wisconsin at Madison

Dr. Leslie Benet, Professor and Chairman of the Department of Pharmacy at the University of California, San Francisco and founder and Chairman of the Board for AvMax, Inc.

Dr. Ronald T. Borchardt, Professor and Chairman of Department of Pharmaceutical Chemistry at the University of Kansas

May 17, 1996 ***The Future of Product Regulation***

Ellen C. Cooper, M.D., Vice President and Director of the Department of Clinical Research and Information for the American Foundation for AIDS Research (AmFAR)

Kenneth Kaitin, Ph.D., Associate Director, Tufts Center for the Study of Drug Development, Tufts University

Marguerite Donoghue, R.N., M.S.N., Co-Director, FDA Council

Jonathan Peck, Managing Director, Institute for Alternative Futures.

June 21, 1996 ***The Future of International Pharmaceutical Markets***

Harvey Bale, Jr., Ph.D., Senior Vice President, International Affairs, PhRMA

Tim Sayles, Pharm.D., Ciba-Geigy Corporation

Jonathan Peck, Managing Director, Institute for Alternative Futures.

July 26, 1996 ***Health and the Information Superhighway***

Thomas Tinstman, M.D., Senior Vice President, Cerner Corporation

Robert Bruegel, Ph.D., Clinical Reference Systems Ltd. (CRS)

Hugh Brownstone, Vice President, Strategic Business Development, IMS America (IMSA)

Jonathan Peck, Managing Director, Institute for Alternative Futures

September 20, 1996 ***Patient Rights and Advocacy Organizations in the 21st Century***

Mary Jo Deering, Ph.D., Director, Health Communication and Telehealth Staff, Office of Disease Prevention and Health Promotion, DHHS
Robert Goldberg, MHS, Director of Membership Services, National Health Council
Joseph Henderson, M.D., Dartmouth Medical School
Stephen Lamb, Assistant Vice President for Public Policy, National Committee for Quality Assurance
Molly Mettler, MSW, Project Director, Healthwise Communities Project, Healthwise Inc.

October 25, 1996 ***Innovations in Pharmaceutical Science: Breakthroughs in Neuroscience***

Frederick Goodwin, M.D., Center on Neuroscience, George Washington University
Peter Whitehouse, M.D., Ph.D., Alzheimer's Research Center, Case Western Reserve University
Eric Zillmer, Ph.D., Department of Psychology, Drexel University
Pat Levitt, Ph.D., Department of Neurobiology, University of Pittsburgh School of Medicine

December 10, 1996 ***Issues from the Future: Health by Design or Default***

Visions of Health - Clement Bezold, Ph.D., President, Institute for Alternative Futures
Loyalty, Trust & Personal Health Information - Linda Harris, Ph.D., Director Health Care Systems, Concept Five Technologies
Going Beyond Medicine - Robert Olson, Research Director, Institute for Alternative Futures
Equity, Economics and Demographics in Coming Decades - Jonathan Peck, Vice President, Institute for Alternative Futures

May 9, 1997 ***What's News with Ewe: Cloning, Medical Science and Health Implications***

Julian Cooper, Ph.D., President, PPL Therapeutics
Jim Robl, Ph.D., President, Advanced Cell Technology, Professor, University of Massachusetts
Walter Truett-Anderson, Vice President, Meridian Institute
Gladys White, Ph.D., Director, National Advisory Board on Ethics and Reproduction (NABER)

June 6, 1997 ***Information, Privacy and Health in the Networked World***

Foresight Seminar Topics List

Heider Wagner Hayduk, Esq., Health Care Leadership Council
Andrew S. Ripps, Director, Professional & Government Affairs,
Healthpoint
Lucian Russell, Ph.D., Argonne National Laboratory
Peter Tippet, M.D. Ph.D., National Computer Security Association

July 18, 1997 ***Clinical Development in the 21st Century***

Michael Hurley, M.S., JD, MBA, Director, Venture Consulting, Abbott
Laboratories
Judith Jones, MD, Ph.D., President, The Degge Group
Carl Peck, MD, Professor of Pharmacology & Medicine, Georgetown
University
Theodore Pincus, MD, Professor of Medicine, Vanderbilt University
William Wardell, MD, Senior Scientific Officer, Covance Clinical and
Periapproval Services

October 10, 1997 ***The Future of Health Quality and Outcomes***

Roger Evans, Ph.D., Mayo Clinic
James Fries, MD, Stanford University School of Medicine
William Golden, MD, Center for Clinical Quality Evaluation (CCQE)

November 7, 1997 ***Medicaid, Managed Care and Prevention: Insights for Success***

Eric Baumgartner, M.D., MPH, Texas Department of Health
Janet Shikles, Powers, Pyles, Sutter & Verville
Michael Nolin, Deputy Director, Managed Care Programs, University of
Maryland Baltimore County

December 5, 1997 ***Aging Ain't What It Use to Be: The Demographic Challenge to
Medicare and other Government Policies***

Robert Blancato, Matz, Shea, Blancato, Public and Government Relations
S. Jay Olshansky, Ph.D., University of Chicago
Deborah Steelman, Law Offices of Deborah Steelman

Foresight Seminar Topics List

- March 13, 1998 ***Information Solutions for Health Systems Management***
- Senator Conrad Burns, (R) Montana
Col. Gail Maestas, Triservice Corporate Executive Information Systems (DoD)
Phil Newbold, Health Care Technologies, SAIC
Dr. Don Lindberg, National Library of Medicine
- June 5, 1998 ***From Hindsight to Foresight: Lessons Learned from Waxman-Hatch 1984-1998***
- W. Douglas Campbell, Fleishman Hillard
Steven A. Grossman, Hill and Knowlton
- November 12, 1998 ***Balancing The Future With The Present: Foresight For Drug Price Competition and Patent Term Restoration***
- Bruce Downey, Barr Laboratories
Kay Holcombe, Policy Directions Inc.
Jeffrey Stritar, Pfizer
- February 9, 1999 ***Policy Implications of Complementary and Alternative Therapies***
- Brian Berman, MD, University of Maryland
Louis Sportelli, DC, Triad Healthcare Inc.
John Weeks, The Integrator
- February 26, 1999 ***New Threats: Infectious Diseases and Drug Resistant Pathogens***
- Dr. Sue Binder, Centers for Disease Control and Prevention (CDC)
Dr. Claire M. Fraser, The Institute for Genomic Research (TIGR)
Dr. Glenn Tillotson, Bayer
- May 31, 2002 ***Medicare Futures: Generational Perspectives & New Medical Technologies***
- Neil Howe, Author and National Speaker
Dr. Joshua Cohen, Tufts Center for the Study of Drug Development
- October 25, 2002 ***Bioterrorism: Leveraging Science & Policy Approaches***
- Susan Neely, Office of Homeland Security
Dr. Kenneth Alibek, George Mason University
Dr. Michael Osterholm, University of Minnesota

January 24, 2003 *Misconceptions & Potential from the Human Genome*

Dr. Alan Guttmacher, National Human Genome Research Institute
Dr. Allen David Roses, Genetics Research, GlaxoSmithKline
Dr. Christopher Webster, Millennium Pharmaceuticals
Dr. Robert Wells, Affymetrix, Inc

June 6, 2003 *The Next Wave of Healthcare Reform*

Dr. Glenna Crooks, Strategic Health Policy International. Inc
Dr. William Rowley, Institute for Alternative Futures
Dr. Gail Warden, Henry Ford Health System

October 30, 2003 *Rethinking Payment Systems for the Future*

Richard Sorian, National Committee for Quality Assurance (NCQA)
Stuart Guterman, Centers for Medicare and Medicaid Services (CMS)

December 16, 2003 *Evolving Payments for Improved Care*

Gerard Anderson, Robert Wood Johnson Foundation
Dr. Timothy Ferris, Partners/ MGH Institute for Health Policy
Judith Hibbard, University of Oregon